News
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Trial Enrolling Well, with Approximately 25% of Targeted Subjects Recruited Top-line Data Expected in First Half of 2019
Group K Diagnostics is the Technology Category Winner in the 2018 Stellar Startup Awards
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
– Dr. Heron Adds Deep Expertise in Orphan Drug Development and Commercialization –
Ossianix and Novo Nordisk sign Research and Option Agreement on Blood Brain Barrier delivery technology for proteins in diabetes and other metabolic diseases
Cohero Health Announces Additions to Executive Leadership Team
Company appoints executives with proven industry experience in connected care, medical device, and pharma to drive growth of the BreathSmart® digital platform for asthma and COPD
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Top-Line Data Expected in First Half of 2019
IView Therapeutics Closes its A round financing to move forward IView-1201, a novel sustain release povidone iodine gel forming solution, into phase II clinical trials for the treatment of adenoviral conjunctivitis
AARP, startups partner to study digital healthcare technology
Clinicians and groups like AARP view in-home digital technology as the future healthcare and are studying different technologies to assist patients in home.